Another Patient Dies in Astellas’ Gene Therapy Trial, FDA Issues New Clinical Hold

Astellas Pharma reported the fourth death from its gene therapy trial for AT132 for the treatment of X-linked myotubular myopathy (XLMTM) on September 14. It also revealed that the US FDA has issued a new clinical hold. The Japanese pharma...read more